Table 2.

Efficacy outcomes

OutcomeACE Inhibitor, n=413, n (%)ARB, n=414, n (%)ACE Inhibitor + ARB, n=416, n (%)ACE Inhibitor Versus ARB, Hazard Ratio (95% CI)ACE Inhibitor Versus Combination, Hazard Ratio (95% CI)ARB Versus Combination, Hazard Ratio (95% CI)
Composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization secondary to cardiovascular cause)30 (7.3)29 (7.0)40 (9.6)1.05 (0.63 to 1.75)0.75 (0.47 to 1.21)0.71 (0.44 to 1.15)
All-cause mortality15 (3.6)20 (4.8)18 (4.3)0.76 (0.39 to 1.48)0.84 (0.42 to 1.67)1.11 (0.59 to 2.10)
Cardiovascular death6 (1.5)7 (1.7)4 (1.0)0.87 (0.29 to 2.58)1.51 (0.43 to 5.36)1.75 (0.51 to 5.97)
ESRD6 (1.5)2 (0.5)4 (1.0)3.04 (0.61 to 15.0)1.53 (0.43 to 5.44)0.50 (0.09 to 2.76)
Nonfatal myocardial infarction4 (1.0)4 (1.0)10 (2.4)1.00 (0.25 to 4.01)0.41 (0.13 to 1.29)0.40 (0.13 to 1.28)
Nonfatal stroke4 (1.0)2 (0.5)5 (1.2)2.02 (0.37 to 11.0)0.81 (0.22 to 3.01)0.40 (0.08 to 2.05)
Hospitalization for cardiovascular cause25 (6.1)20 (4.8)34 (8.2)1.27 (0.71 to 2.29)0.74 (0.44 to 1.25)0.58 (0.34 to 1.01)
Doubling of serum creatinine21 (5.1)19 (4.6)23 (5.5)1.12 (0.60 to 2.08)0.95 (0.53 to 1.74)0.85 (0.46 to 1.57)
Progression to eGFR<60 ml/min per 1.73 m2a71 (30.1)75 (33.0)65 (31.7)0.88 (0.63 to 1.21)0.97 (0.70 to 1.37)1.11 (0.79 to 1.55)
Progression to severe albuminuria46 (14.4)49 (15.2)41 (13.0)0.86 (0.57 to 1.29)1.04 (0.68 to 1.59)1.21 (0.80 to 1.83)
Regression to normal or mildly increased albuminuria83 (20.6)86 (21.6)92 (22.7)0.94 (0.69 to 1.27)0.90 (0.67 to 1.22)0.96 (0.72 to 1.29)
  • Counts correspond to the number of participants who experienced a specific outcome event at least once. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; 95% CI, 95% confidence interval.

  • a In participants with an eGFR>60 ml/min per 1.73 m2 at baseline (ACE inhibitor, n=236; ARB, n=227; ACE inhibitor + ARB, n=205).